See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Social Media
Eid
Tariffs
Donald Trump
US Politics
Artificial Intelligence
Stock Markets
Education
Taxes
Senate
Baseball
Published • loading... • Updated

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer - Genmab (NASDAQ:GMAB)

Summary by Benzinga
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan. The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK …

5 Articles

All
Left
Center
2
Right
BenzingaBenzinga
Center

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer - Genmab (NASDAQ:GMAB)

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan. The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK …

·New York, United States
Read Full Article
Hastings TribuneHastings Tribune
Center

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

COPENHAGEN, Denmark--(BUSINESS WIRE)--Mar 27, 2025-

Read Full Article
cancernetwork.comcancernetwork.com

Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer

Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Genmab’s Tivdak approved in Japan for advanced cervical cancer

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

Read Full Article
onclive.comonclive.com

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Thursday, March 27, 2025.
Sources are mostly out of (0)

Similar News Topics

Cancer

Cancer

Copenhagen

Copenhagen

Japan

Japan

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal